Teacher Retirement System of Texas Buys 292,477 Shares of Embecta Corp. $EMBC

Teacher Retirement System of Texas increased its stake in Embecta Corp. (NASDAQ:EMBC) by 365.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 372,451 shares of the company’s stock after acquiring an additional 292,477 shares during the quarter. Teacher Retirement System of Texas’ holdings in Embecta were worth $5,255,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Embecta in the 3rd quarter worth approximately $173,000. Inspire Advisors LLC raised its stake in Embecta by 8.6% during the third quarter. Inspire Advisors LLC now owns 38,006 shares of the company’s stock worth $536,000 after buying an additional 3,007 shares during the last quarter. Ritholtz Wealth Management acquired a new position in Embecta in the third quarter valued at $246,000. Nisa Investment Advisors LLC lifted its holdings in Embecta by 327.2% in the third quarter. Nisa Investment Advisors LLC now owns 48,809 shares of the company’s stock valued at $689,000 after buying an additional 37,384 shares during the period. Finally, A&I Financial Services LLC bought a new stake in Embecta during the third quarter valued at $912,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Embecta presently has a consensus rating of “Hold” and a consensus price target of $18.50.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $10.74 on Tuesday. Embecta Corp. has a 52-week low of $9.20 and a 52-week high of $19.67. The business’s 50 day simple moving average is $12.30 and its two-hundred day simple moving average is $12.96. The firm has a market cap of $635.92 million, a P/E ratio of 6.59 and a beta of 1.11.

Embecta (NASDAQ:EMBC) last issued its earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The company had revenue of $263.30 million for the quarter, compared to analyst estimates of $265.66 million. During the same period in the prior year, the firm earned $0.45 earnings per share. Embecta’s revenue for the quarter was down 7.7% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Friday, December 5th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.6%. The ex-dividend date was Friday, December 5th. Embecta’s dividend payout ratio (DPR) is currently 36.81%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.